Managed Care Organizations are reviewing drugs well before a product is approved. According to a survey conducted by Dymaxium (the company behind the AMCP eDossier System) and presented in a recent webinar, two out of three healthcare decision makers begin to evaluate a drug at least six months prior to approval. The survey also indicates that the primary source of information that payers are using for these pre-approval evaluations is clinicaltrials.gov (CT.gov), and that manufacturers are not always responsive to requests for information pre-approval.
It has become tradition at Advera Health to look closely at the annual formulary exclusions that the large payers such as Express Scripts introduce every August. Using our safety scoring and costing algorithms we are able to quickly provide a top-line view into the effects of their decisions.
In the past several weeks Express Scripts and CVS Healthcare have announced exclusivity deals with Abbvie and Gilead respectively, for their Hepatitis C medications. The deals offer access to the extremely costly medications that have been previously denied formulary inclusion by these massive PBMs.
I read an interesting opinion piece in the Wall Street Journal recently titled Of Ferguson and Fallujah. In his essay Bret Stephens (@StephensWSJ) intends to compare President Obama’s foreign policy to the police response to the extremely unfortunate events that have been, and continue to be unfolding in Ferguson, MO. His view is that both are “disastrously reactive”.
To support his opinion, he uses the broken windows theory. Developed by George Kelling and James Q. Wilson, and written about in a 1982 Atlantic Monthly article. The title comes from the following example: